LLY
Eli Lilly and Company
LLY has the edge over NUTX overall, supported by lower modeled downside and stronger fundamentals.
NUTX
Nutex Health, Inc.
NUTX's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NUTX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Strong | |
| Strong | |
| Strong |
NUTX's profitability, cash flow and balance sheet are currently strong, but its revenue is under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NUTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 6.4x | $171 | — |
| Current | 7.2x | $171 | — |
| Cheap | 7.3x | $174 | +1.7% |
| Fair | 8.7x | $208 | +21% |
| Expensive | 11x | $255 | +49% |
Historical ranges are pointers, not guarantees.
NUTX has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over NUTX on the outlook, with more favorable revenue expectations.
NUTX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect NUTX's earnings to grow and its profitability to improve, with its revenue holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
NUTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $26.68 | +11% |
| Q3 2026 | $23.95 | +24% |
| Q2 2026 | $26.00 | +166% |
| Q1 2026 | $13.67 | +8% |
| Q4 2025 | $10.48 | +14% |
| Q3 2025 | $19.26 | +$28.65 |
| Q2 2025 | $9.78 | +$18.95 |
| Q1 2025 | $12.66 | +$23.26 |
| Q4 2024 | $9.23 | +$21.23 |
NUTX's earnings per share have climbed steadily: $23.95 over the past year, up 24% from the year before, and higher year over year for eight quarters in a row.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
NUTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $217.6M | -19% |
| Q2 2026 | $210.8M | -14% |
| Q1 2026 | $216.5M | +2.2% |
| Q4 2025 | $151.7M | -41% |
| Q3 2025 | $267.8M | +240% |
| Q2 2025 | $244M | +221% |
| Q1 2025 | $211.8M | +214% |
| Q4 2024 | $257.6M | +270% |
NUTX's revenue has slid since its 2025 peak: $218M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 35% | -13 points |
| Q2 2026 | 58% | +44 points |
| Q1 2026 | 38% | -0.6 points |
| Q4 2025 | 20% | -24 points |
| Q3 2025 | 49% | +36 points |
| Q2 2025 | 14% | +6.8 points |
| Q1 2025 | 38% | +36 points |
| Q4 2024 | 44% | +82 points |
NUTX has the edge over LLY on profitability, with a higher operating margin.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
NUTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $73.1M | -26% |
| Q2 2026 | $31.7M | +19% |
| Q1 2026 | $74.3M | +46% |
| Q4 2025 | $69M | +$69.3M |
| Q3 2025 | $99.2M | +1507% |
| Q2 2025 | $26.5M | +109% |
| Q1 2025 | $50.9M | +2096% |
| Q4 2024 | -$341.8K | +$608.8K |
NUTX has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NUTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +20.7K shares |
| 1 year | -1.9% | -136K shares |
| 3 years | +59% | +2.6M shares |
NUTX has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1,000 |
| Q2 2026 | $19M |
| Q1 2026 | $31.7M |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
NUTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.6x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.5x | Net Cash |
| Q3 2025 | -0.3x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.2x | Net Cash |
| Q4 2024 | -0.0x | Net Cash |
NUTX has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NUTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.5 | Neutral |
| Stochastic | 42.9 | Neutral |
NUTX's weekly RSI is 48 (neutral) and its Stochastic is 43 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NUTX PE vs Healthcare Sector
| Metric | NUTX | Sector median | Relative |
|---|---|---|---|
| PE | 7.2x | 26x | 72% below |
| PE % | 13 | 29 | 16 pts below |
NUTX has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over NUTX on trend strength, trading above more of its moving averages.
NUTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $198.8 | 14% below |
| 20 week MA | $187.7 | 8.7% below |
| 50 week MA | $153.5 | 12% above |
| 100 week MA | $123.4 | 39% above |
| 200 week MA | $86.9 | 97% above |
NUTX has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 97% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over NUTX on returns for 2026, with the stronger performance.
NUTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $301.5 | $157.5 | -48% |
| 2021 | $157.5 | $619.5 | +293% |
| 2022 | $619.5 | $312.0 | -50% |
| 2023 | $312.0 | $27.0 | -91% |
| 2024 | $27.0 | $31.9 | +18% |
| 2025 | $31.9 | $176.7 | +455% |
| 2026 YTD | $176.7 | $171.4 | -3% |
NUTX's yearly returns have swung widely, from +455% in 2025 to −91% in 2023. It's down 3% so far in 2026.